PaxVax to expand typhoid vaccine
PaxVax, a vaccine company that specializes in travel and biodefense, said the partnerships will guarantee that Vivotif will be made available to people in Europe and Australia in addition to the U.S., which already has access to Vivotif. PaxVax’s marketing and direct sales have continued to grow in its current commercial networks, but the company is seeking to expand as its license for sale is valid in 27 countries.
In July 2014, PaxVax acquired Vivotif. Since then, the company has developed commercial infrastructure and legal entities around the world, including in the U.K., Italy, Switzerland and Spain. Some of its partnered distributors are Polar Speed (U.K.) and Alloga (Italy, Switzerland and Spain).
"Typhoid is one of the most commonly delivered travel vaccines, and these agreements will ensure the availability of Vivotif to people in the European and Australian markets who are travelling to regions of the world where typhoid is endemic," PaxVax President and COO Nima Farzan said. "Vivotif is the only oral vaccine indicated for typhoid and we look forward to working with our new distribution partners to maintain a stable global supply of this effective vaccine."